Загрузка...
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE anti...
Сохранить в:
| Опубликовано в: : | Nat Commun |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group UK
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6949303/ https://ncbi.nlm.nih.gov/pubmed/31913280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-13815-w |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|